Novo Nordisk and Celgene lead January pharma M&A
Novo’s bid
Pharma M&A could surge in 2017, says report
Deal expected to be worth around $30 billion.
Bid of $20 million may be enough to acquire all of BIND’s assets.
The specialist pharma company is set to expand into osteoporosis through its partnership with Amgen